Moustafa Gabr

Assistant Professor

Weill Cornell Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Moustafa Gabr is an Assistant Professor at Weill Cornell Medicine in the United States. His research focuses on cancer immunotherapy and includes recent work on targeted small molecules, CAR therapies, and novel inhibitors for glioblastoma. He utilizes innovative screening methodologies such as TRIC technology for drug discovery and optimization.

Articles (20)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

F. Christopher Pigge

Iowa State University

UNITED STATES

View details

Walter Becker

Medizinische Fakultät der RWTH Aachen

GERMANY

View details

Gerhard Wolber

Professor

Freie Universität Berlin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Moustafa Gabr

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Discovery and validation of LAGi-DEL: A nanomolar LAG-3 inhibitor that reverses immune suppression in tumor-immune co-culture models

Designing immunity with cytokines: A logic-based framework for programmable CAR therapies

CHI3L1-targeted small molecules as glioblastoma therapies: Virtual screening-based discovery, biophysical validation, pharmacokinetic profiling, and evaluation in glioblastoma spheroids

Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid models

First-in-class dual inhibitors of MASTL and Aurora A kinase: Discovery of selective cyclohexa[b]thiophenes with potent anticancer activity

Orthogonal temperature-related intensity change (TRIC) and TR-FRET as a high-throughput screening platform for the discovery of SLIT2 binders: A proof-of-concept approach

Structure-Based Virtual Screening Identifies Potent CD28 Inhibitors That Suppress T Cell Co-stimulation in Cellular and Mucosal Models

TREM2 hit discovery using temperature-related intensity change (TRIC) technology: A proof-of-concept high-throughput screening approach

Temperature-related intensity change (TRIC)-based high-throughput screening enables the discovery of small molecule CD28 binders

Discovery and Optimization of LAG-3-Targeted Small Molecules via DNA-Encoded Chemical Library (DEL) Screening for Cancer Immunotherapy

Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening

Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction

Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3)

Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells

Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for <sup>203</sup>Pb and <sup>212</sup>Pb-Based Theranostics

First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects

AIE Luminogens as Versatile Bioprobes

Peptidomimetic‐based approach toward inhibitors of microbial trimethylamine lyases

Mechanism of zinc ejection by disulfiram in nonstructural protein 5A

Collaborators (3)

F. Christopher Pigge

Walter Becker

Gerhard Wolber

Make your next move.